BioCentury
ARTICLE | Company News

China’s NMPA approves Innovent’s PD-1 mAb Tyvyt for Hodgkin lymphoma

December 27, 2018 11:02 PM UTC

China's National Medical Products Administration approved anti-PD-1 mAb Tyvyt sintilimab (IBI308) from Innovent Biologics Inc. (HKSE:1801) to treat relapsed or refractory classical Hodgkin lymphoma. Tyvyt brings the country's slate of approved PD-1 inhibitors to at least four, covering three indications.

Co-developed by Innovent and Eli Lilly and Co. (NYSE:LLY), Tyvyt is Innovent's first approved therapy. The approval comes two months after the Chinese company debuted on the Hong Kong stock exchange (see "Innovent's Hong Kong Spark")...